Advanced Development of a Vaccine for Acute Flaccid Myelitis Associated with Enterovirus D68

To support the advanced development of candidate products for use following the intentional release of or in response to naturally occurring outbreaks of infectious diseases caused by NIAID Category A, B, and C Priority Pathogens or emerging infectious diseases. This contract may support formulation and manufacture of the individual vaccine components, as well as stability testing, nonclinical immunogenicity and efficacy testing in animal models, IND enabling GLP toxicology, submission of an IND and clinical safety and efficacy evaluation. This project focuses on the development of an Acute Flaccid Myelitis vaccine for pediatric populations and includes a Phase I clinical trial.